BiotechTube

MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal spray

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rhinitis, Allergic, Perennial

Conditions

Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal

Trial Timeline

Jan 1, 2013 โ†’ Apr 1, 2015

NCT ID
NCT01700192

About MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal spray

MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal spray is a phase 3 stage product being developed by Merck for Rhinitis, Allergic, Perennial. The current trial status is completed. This product is registered under clinical trial identifier NCT01700192. Target conditions include Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01700192Phase 3Completed

Competing Products

20 competing products in Rhinitis, Allergic, Perennial

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
77
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
85
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
33
ciclesonide + mometasoneSumitomo PharmaPhase 3
77
DSP-3025 + PlaceboSumitomo PharmaPhase 1
33
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
77
ciclesonide HFA 160 ฮผgSumitomo PharmaPhase 3
77
Ciclesonide HFA 160 ฮผg + Ciclesonide HFA 80 ฮผg + PlaceboSumitomo PharmaPhase 3
77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
MavencladยฎApproved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85